 |
|
USC researchers find new clues to risk of Hodgkin lymphoma
April 02, 2008Unique study of twins offers new hypothesis on why disease affects some, and not others
A long-term study of twins has led University of Southern California (USC) researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein (interleukin-12).
"We found that lower levels of the protein interleukin-12, involved in fighting intracellular infections, increases susceptibility to young adult Hodgkin lymphoma," says Wendy Cozen, D.O., M.P.H, associate professor of preventive medicine at the Keck School of Medicine of USC. " Cozen is lead author on the study entitled, "Interleukin-2, interleukin-12, and interferon-¦Ã levels and risk of young adult Hodgkin lymphoma," published in the April 1 issue of the journal, Blood.
The study is accompanied by an editorial entitled "Hodgkin twins: double good, double trouble," by Richard F. Ambinder of the Johns Hopkins School of Medicine.
The work is based on patient populations found in the International Twin Study and California Twin Program, unique registries of twin pairs developed and maintained in the Department of Preventive Medicine at USC.
Hodgkin lymphoma is the most common type of cancer among young women and the second most common type among young men. But while the 5-year survival rate is high compared to that of other cancers, the treatment may cause complications later in life.
According to Cozen, this study, along with a previous one her group published in 2007, provides the first clear evidence that individual differences in immune response (via cytokine secretion) may lead to the development of Hodgkin lymphoma.
"We previously showed that there is a substantial genetic risk for adolescent and young adult Hodgkin lymphoma, and that another immune response protein (interleukin-6) was related to risk," says Cozen. "We are pursuing the hypothesis that variations in genes control the secretion of these immune response proteins (cytokines) predicting Hodgkin lymphoma risk."
Eventually, based on the group's current work, researchers may be able to develop novel treatments to correct the abnormal immune response thereby offering alternatives to current therapy.
Cozen and her group are conducting an expanded study among adolescent and young adult Hodgkin lymphoma patients and their parents in Los Angeles.
The group is studying these genes and others that control the immune response in hopes of confirming their previous results and to further define the inherited patterns that explain the genetic part of the risk.
Cozen adds that colleagues from the National Cancer Institute and Washington University in St. Louis, will also be studying early exposures to infectious agents such as bacteria and viruses, which may interact with the immune system leading to Hodgkin lymphoma.
University of Southern California
The study is accompanied by an editorial entitled "Hodgkin twins: double good, double trouble," by Richard F. Ambinder of the Johns Hopkins School of Medicine.
The work is based on patient populations found in the International Twin Study and California Twin Program, unique registries of twin pairs developed and maintained in the Department of Preventive Medicine at USC.
Hodgkin lymphoma is the most common type of cancer among young women and the second most common type among young men. But while the 5-year survival rate is high compared to that of other cancers, the treatment may cause complications later in life.
According to Cozen, this study, along with a previous one her group published in 2007, provides the first clear evidence that individual differences in immune response (via cytokine secretion) may lead to the development of Hodgkin lymphoma.
"We previously showed that there is a substantial genetic risk for adolescent and young adult Hodgkin lymphoma, and that another immune response protein (interleukin-6) was related to risk," says Cozen. "We are pursuing the hypothesis that variations in genes control the secretion of these immune response proteins (cytokines) predicting Hodgkin lymphoma risk."
Eventually, based on the group's current work, researchers may be able to develop novel treatments to correct the abnormal immune response thereby offering alternatives to current therapy.
Cozen and her group are conducting an expanded study among adolescent and young adult Hodgkin lymphoma patients and their parents in Los Angeles.
The group is studying these genes and others that control the immune response in hopes of confirming their previous results and to further define the inherited patterns that explain the genetic part of the risk.
Cozen adds that colleagues from the National Cancer Institute and Washington University in St. Louis, will also be studying early exposures to infectious agents such as bacteria and viruses, which may interact with the immune system leading to Hodgkin lymphoma.
University of Southern California
Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News RSSChildhood cancer survivors experience suicidal thoughts decades after diagnosis
Adult survivors of childhood cancer have an increased risk for suicidal thoughts, even decades after their cancer treatments ended, according to a study led by Dana-Farber Cancer Institute scientists.
Experimental drug lets B cells live and lymphoma cells die
An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.
Research identifies successful new treatment for Hodgkin's lymphoma, reduces long-term risks
New research led by Cindy Schwartz, MD, of Hasbro Children's Hospital has identified a new chemotherapy regimen for pediatric Hodgkin lymphoma (HL) patients.
Anti-inflammatory drugs may defeat a treatment-resistant type of cancer
Effective drugs for treating a chemotherapy-resistant form of lymphoma might already be on the market according to a study that has pieced together a chemical pathway involved in the disease.
Two targeted therapies likely better than one in patients with aggressive lymphoma
When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG).
Do patients at risk for B-cell malignancy need antiviral treatment?
Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists. However the precise mechanism remains unclear.
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.
New therapy prevents dangerous side effect for lymphoma patients
Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.
Novel treatments show improvements in survival and response rates for leukemia and lymphoma
The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse.
Novel therapeutic approaches may improve patient outcomes in several platelet disorders
Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood.
More Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News Articles
 |
Hodgkin Lymphoma by Richard T Hoppe (Editor), Peter M Mauch (Editor), James O Armitage (Editor), Volker Diehl (Editor), Lawrence M Weiss (Editor) The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up. This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment options—including combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantation—and offer guidelines for treatment selection. Full consideration is given to late effects of therapy and clinical trials for assessing quality of life in patients. This edition includes... |
 |
Victor Not Victim: My Battle with Hodgkin's Lymphoma by Dr. Mark Gugliotti PT (Author) Throughout his career in physical therapy Mark had been accustomed to helping others who depended on his expertise for their rehabilitative care. Imagine his surprise when he sought medical attention for a "nagging cough" and soon learned he had Hodgkin's Lymphoma. Now, his diagnosis forced him to rely on other experts. Victor Not Victim is Mark's personal journey of his diagnosis, treatment, and eventual resolution. It's the inspirational story of a cancer survivor told from the point of view of a medical practitioner faced, as a lay person, with the challenge of surviving a devastating illness. In this book Mark attempts to provide a unique insight to his battle with cancer. His casual style is intended to capture the same conversational tone shared with other patients he met along the... |
 |
Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options by Lorraine Johnston (Author) The sixth most common cancer, non-Hodgkin's lymphomas (NHL) affect 300,000 people in the U.S., with 60,000 new patients diagnosed yearly. Treatment has been difficult, and prognosis for low-grade lymphoma especially has been dim. Research in NHL, however, is robust and promising. In this fast-moving treatment environment, all but super-specialist MDs find it hard to keep abreast of changes that affect the treatments and lives of NHL patients. Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment & Options helps those living with this disease to participate in wise treatment decisions. The book discusses in depth: Current treatment options Clinical trials and promising future treatments How NHL is different from other cancers Coping with tests, symptoms, and treatment side... |
 |
Beating Pregnancy and Hodgkin's Lymphoma Together Sweatshirt X-Large White by Shop Zeus |
 |
Non-Hodgkin's Lymphoma Awareness Ribbon Mouse Pad by MyHeritageWear.com The Non-Hodgkin's Lymphoma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Non-Hodgkin's Lymphoma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Non-Hodgkin's Lymphoma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Hodgkin Lymphoma Hardbound Textbook- Second Edition by lippincott and williams The definitive text on Hodgkin lymphoma is now in its thoroughly revised, updated Second Edition. More than 100 recognized authorities from all parts of the world provide comprehensive, current information on every aspect of Hodgkin lymphoma, including etiology, epidemiology, biology, pathology, evaluation, staging, treatment, and follow-up. This edition describes the increased use of PET scanning in staging and follow-up. Chapters discuss current treatment optionsincluding combination chemotherapy, radiation therapy, novel treatment techniques, and hematopoietic stem cell transplantationand offer guidelines for treatment selection. Full consideration is given to late effects of therapy and clinical trials for assessing quality of life in patients. This edition includes complete access... |
 |
2009 Conquering Cancer - The Empowered Patient's Complete Reference to Non-Hodgkin Lymphoma - Diagnosis, Treatment Options, Prognosis (Two CD-ROM Set) by PM Medical Health News (Author) This up-to-date and comprehensive set of two CD-ROM discs provides a superb collection of official Federal government documents on Non-Hodgkin Lymphoma: signs and symptoms, diagnosis, lab tests, treatment and management options, and ongoing clinical research. Every aspect of the disease is thoroughly covered. Non-Hodgkin lymphomas are a large group of cancers of the immune system and are often marked by enlarged lymph nodes, fever, and weight loss. There are many different types of non-Hodgkin lymphomas which can be divided into aggressive (fast-growing) and indolent (slow-growing) types and can be classified as either B-cell or T-cell non-Hodgkin lymphoma. B-cell non-Hodgkin lymphomas include Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell... |
 |
Beating Pregnancy and Non-Hodgkin's Lymphoma Together Mug by Design a Product LLC Text on mug: Beating Pregnancy and Non-Hodgkin's Lymphoma Together * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
 |
ABC News Nightline Life and Death: Episodes 1-4 'Life and Death,'' chronicles the journey of four people facing life threatening illnesses, as they struggle with their families to battle despair and celebrate life. EPISODE 1: FINDING A DONOR: Stephen Dzemian is trying to find a live donor to risk his or her own life to save him. EPISODE 2: A MOTHER'S ILLNESS: Aimee Chamernik is dieing of amyotrophic lateral sclerosis -- the illness known as Lou Gehrig's disease. EPISODE 3: FRANK'S STORY: Frank O'Day who is battling Stage 4 Hodgkin's Lymphoma. EPISODE 4: DIEING WITH DIGNITY: Glenn Elfman, who was diagnosed with cancer that is terminal, discusses physician-assisted suicide with his wife. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Hodgkin's and Non-Hodgkin's Lymphoma (Cancer Treatment and Research) by John P. Leonard (Editor), Morton Coleman (Editor) Over recent years, there has been a dramatic increase in knowledge of the biology of the lymphomas which has been accompanied by the emergence of new treatments that offer both improvements in efficacy and reduction in toxicity. Molecular profiling of tumor tissue and other new advances have led to a better understanding of the genetic basis of lymphoma, identification of new therapeutic targets, and potentially valuable prognostic information. Monoclonal antibody therapies, radioimmunoconjugates and other new agents such as proteosome inhibitors are providing important new treatment options for patients. In this volume, an internationally recognized group of experts provides a comprehensive overview of the biology, pathology, standard treatments, and novel approaches in management of... |
| © 2009 BrightSurf.com |